(0)
Agreement builds on successful preclinical studies in gastrointestinal cancers through the joint Virtual Research and Development Center (VRDC)
The continued collaboration will explore lung cancer targeting KRAS and TRAILR2 molecules from Boehringer Ingelheim s growing portfolio of cancer treatments and builds on its commitment to delivering first-in-class treatment options to people living with cancer
Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center today announced the extension and expansion of their joint Virtual Research and Development Center (VRDC) to explore new molecules from Boehringer Ingelheim s KRAS (Kirsten rat sarcoma) and TRAILR2 (TNF-related apoptosis-inducing ligand receptor 2) portfolios for the potential treatment of lung cancer, particularly non-small cell lung cancer.
Boehringer Ingelheim and Zealand Pharma Advance to Phase 2 Clinical Testing in NASH and Obesity sina.com.tw - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sina.com.tw Daily Mail and Mail on Sunday newspapers.
New studies mark an important advancement of Boehringer Ingelheim's cardiometabolic focus areas obesity and NASH. The GLP-1/glucagon dual agonist BI 456906 may offer important benefits on
Boehringer Ingelheim and The Lieber Institute for Brain Development to Collaborate to Develop Centrally Acting COMT Inhibitors for Treatment of Neuropsychiatric Disorders businesswireindia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businesswireindia.com Daily Mail and Mail on Sunday newspapers.
(1)
Through the partnership with the Lieber Institute, Boehringer Ingelheim obtains access to preclinical pipeline candidates of a potential first-in-class approach for the symptomatic treatment of neuropsychiatric disorders, including schizophrenia.
The new collaboration further expands Boehringer Ingelheim s circuitry-based approach to precision psychiatry and solidifies the company s commitment to provide better treatments for patients living with serious mental health conditions.
Boehringer Ingelheim and the Lieber Institute for Brain Development (LIBD) today announced a joint research and licensing collaboration focused on the development of novel centrally acting COMT (catechol-O-methyltransferase) inhibitors for the potential treatment of cognitive deficits in a spectrum of neuropsychiatric disorders, including schizophrenia. Aligning with a circuitry-based approach to precision psychiatry, the collaboration will leverage Boehringer Ingelheim s deep experience in central n